Influence of Vorapaxar on Thrombin Generation and Coagulability
Coronary Artery Disease · Peripheral Vascular Disease
Enrolment: 81 · Results not recorded
Loading the evidence…
Drug · PAR-1 (thrombin receptor) antagonist; antiplatelet.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Coronary Artery Disease · Peripheral Vascular Disease
Enrolment: 81 · Results not recorded
Myocardial Infarction · Diabetes Mellitus · Peripheral Arterial Disease
Enrolment: 66 · Results not recorded
Myocardial Infarction
Enrolment: 130 · Results not recorded
Peripheral Artery Disease
Enrolment: 0 · Results not recorded
Atherosclerosis · Myocardial Ischemia · Myocardial Infarction
Enrolment: 12944 · Results not recorded
Atherosclerosis · Myocardial Infarction · Cerebrovascular Accident
Enrolment: 258 · Results not recorded
Acute Coronary Syndrome
Enrolment: 120 · Results not recorded
AV Fistula
Enrolment: 17 · Results not recorded
Cerebral Infarction
Enrolment: 90 · Results not recorded
HIV
Enrolment: 65 · Results not recorded
Acute Coronary Syndrome
Enrolment: 173 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Doxorubicin-induced cardiotoxicity, acute model using a single intraperitoneal dose of 20 mg/kg with function assessed at 5 days, and chronic model using 5 mg/kg weekly for 5 weeks to a cumulative 25 mg/kg at 35 days
PAR-1 deficient mice showed less cardiac injury, oxidative stress, apoptosis and inflammation and better preserved cardiac function after both acute and chronic doxorubicin exposure, and vorapaxar treatment of wild-type mice reduced acute doxorubicin-induced cardiac dysfunction with no additional e…
Extraction: extract · Supplied extraction confidence: 0.82. Machine-extracted fields require source verification.
Model: Localised fractionated X-irradiation (5 Gy on each of 9 days, 250 kVp, dose rate 4.49 Gy/min) of a 4 cm loop of distal ileum transposed into the scrotum, producing early radiation mucositis and delayed radiation fibrosis
At 2 weeks PAR1 blockade reduced the radiation injury score (p=0.002), myeloperoxidase-positive cells (p=0.03), smooth muscle cell proliferation (p=0.04) and collagen III immunoreactivity (p=0.005) in a dose dependent manner, but neither short-term nor long-term administration altered delayed intes…
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.